Featured News
-
ACLA Files A Motion for Summary Judgment Against HHS In ACLA v. Azar
Washington, D.C. — Following a favorable decision on a jurisdictional question issued by the U.S. Court of Appeals for the D.C. Circuit, the American Clinical Laboratory Association (ACLA) has filed a motion for summary judgment before the U.S. District Court for the District of Columbia challenging the flawed implementation of the Protecting Access to Medicare Act (PAMA) in the final rule promulgated by the U.S. DepartmentContinue Reading »... -
ACLA Comments on CY 2020 OPPS Proposed Rule
... -
ACLA Comments on CY 2020 PFS Proposed Rule
... -
For Seniors in Rural Communities, Erosion of Lab Benefits is an Urgent Threat
One in four seniors in the United States lives in a rural area—a notable statistic considering the unique set of health challenges these communities face. Nearly 80% of rural America is “medically underserved,” according to the federal government. Seniors living in these parts of the country have far fewer options for care and are often required to travel significant distances just to get theContinue Reading »... -
AIM Coalition Letter of Support for The Promoting Integrity in Medicare Act (PIMA), H.R.2143
... -
ACLA Deeply Concerned by FDA Actions on Pharmacogenetic Testing
Agency actions limit clinical information for physicians and patients, undermine Congress and ongoing diagnostic reform efforts Washington, D.C. – In response to the U.S. Food and Drug Administration (FDA)’s troubling actions against pharmacogenetic (PGx) testing, ACLA urged the agency to immediately reconsider and reverse its recent decisions in light of the significant harm and consequences to patient care. Taken together, FDA’s actions appear toContinue Reading »... -
ACLA Statement in Response to U.S. Court of Appeals Ruling in ACLA v. Azar
Court of Appeals Says ACLA is Entitled to Challenge HHS’s Harmful Regulatory Overreach Washington, D.C. — In response to today’s ruling from the U.S. Court of Appeals for the District of Columbia in favor of the American Clinical Laboratory Association (ACLA) in its lawsuit against the Department of Health and Human Services (HHS), ACLA President Julie Khani issued the following statement: “We strongly commend the CourtContinue Reading »... -
National Health Organizations Call on Congressional Leaders to Delay Flawed Reporting Process Jeopardizing Seniors’ Access to Laboratory Care
LAB Act would delay PAMA reporting period in order to improve data collection process for market-based rates WASHINGTON, D.C. – With 53 million Americans facing steep year-over-year cuts to vital clinical diagnostics, 26 national groups representing patient, provider, diagnostic and laboratory organizations called on Congressional leadership to delay a flawed data collection process that continues to erode Medicare lab benefits for the country’s mostContinue Reading »... -
Op-Ed: If Washington takes a short-sighted view, seniors will pay the price
This week, ACLA President Julie Khani published an op-ed in The Hill, responding to a troubling recent proposal by Roger Klein to disregard private payor data and instead impose a spending cap for some tests. As Khani points out, “Such a plan would further erode PAMA’s clear goal of moving to a market-based system in Medicare and would undermine the assurances of a predictableContinue Reading »... -
Statement of The American Clinical Laboratory Association on Automated Chemistry Test Panels Under PAMA
...
